CUSIP 98420N105 · who reports it, how much, and how much it matters to them
45 of the 720 hedge fund managers we track reported shares of Xenon Pharmaceuticals Inc. (Nasdaq: XENE) on Form 13F for 30 June 2026. Between them they reported USD 1.3bn. The largest position belongs to Avoro Capital Advisors, at USD 349m.
Compiled from SEC Form 13F filings · Hedge Fund Intelligence, PPLI.com · updated
Form 13F is filed by the manager and covers all of its accounts, so a position here belongs to the firm, not to any one fund. Not investment advice.
A list of every manager in our coverage that reported this share at the end of the quarter, taken from the filings themselves. Short positions and options are not in it.
Taken from each manager's Form 13F for 30 June 2026. A manager appears here if it reported the shares themselves; positions held only through options are left out.
The bar and the percentage show how much of the manager's reported 13F book the position makes up. Each name opens that manager's largest fund on PPLI.com, where the rest of its book is listed.
| # | Manager | Value reported | Share of its book |
|---|---|---|---|
| 1 | Avoro Capital Advisors1 fund on PPLI.com | USD 349m | 3.1% |
| 2 | Polar Capital LLP26 funds on PPLI.com | USD 276m | 0.7% |
| 3 | Two Sigma Investments35 funds on PPLI.com | USD 99m | 0.1% |
| 4 | Citadel Advisors32 funds on PPLI.com | USD 85m | 0.0% |
| 5 | Braidwell12 funds on PPLI.com | USD 68m | 2.5% |
| 6 | Orbimed Advisors1 fund on PPLI.com | USD 54m | 1.0% |
| 7 | Marshall Wace LLP84 funds on PPLI.com | USD 42m | 0.0% |
| 8 | Rock Springs Capital Management2 funds on PPLI.com | USD 41m | 2.0% |
| 9 | Tudor Investment Corporation10 funds on PPLI.com | USD 33m | 0.0% |
| 10 | Octagon Capital Advisors1 fund on PPLI.com | USD 30m | 2.7% |
| 11 | Logos Global Management1 fund on PPLI.com | USD 27m | 1.2% |
| 12 | Millennium Management6 funds on PPLI.com | USD 23m | 0.0% |
| 13 | Baker Bros. Advisors2 funds on PPLI.com | USD 22m | 0.1% |
| 14 | Adage Capital Management1 fund on PPLI.com | USD 18m | 0.0% |
| 15 | Dafna Capital Management6 funds on PPLI.com | USD 15m | 2.9% |
| 16 | Redmile Group10 funds on PPLI.com | USD 14m | 0.9% |
| 17 | Schonfeld Strategic Advisors30 funds on PPLI.com | USD 14m | 0.0% |
| 18 | D. E. Shaw & Co.15 funds on PPLI.com | USD 14m | 0.0% |
| 19 | Eversept Partners3 funds on PPLI.com | USD 12m | 0.6% |
| 20 | Balyasny Asset Management25 funds on PPLI.com | USD 12m | 0.0% |
| 21 | Renaissance Technologies13 funds on PPLI.com | USD 11m | 0.0% |
| 22 | Boothbay Fund Management2 funds on PPLI.com | USD 11m | 0.1% |
| 23 | POINT72 Asset Management17 funds on PPLI.com | USD 7.9m | 0.0% |
| 24 | Squarepoint Ops7 funds on PPLI.com | USD 6.8m | 0.0% |
| 25 | Sphera Funds Management1 fund on PPLI.com | USD 6.3m | 0.8% |
| 26 | Burkehill Global Management5 funds on PPLI.com | USD 6m | 0.2% |
| 27 | Exoduspoint Capital Management7 funds on PPLI.com | USD 5.1m | 0.0% |
| 28 | Capital Fund Management S.A.12 funds on PPLI.com | USD 5.1m | 0.0% |
| 29 | Walleye Capital8 funds on PPLI.com | USD 4.6m | 0.0% |
| 30 | Artia Global Partners1 fund on PPLI.com | USD 3.9m | 0.7% |
| 31 | Engineers Gate Manager1 fund on PPLI.com | USD 3.8m | 0.0% |
| 32 | Palo Alto Investors6 funds on PPLI.com | USD 3.1m | 0.4% |
| 33 | Verition Fund Management3 funds on PPLI.com | USD 2.4m | 0.0% |
| 34 | Aquatic Capital Management3 funds on PPLI.com | USD 2.3m | 0.1% |
| 35 | HighVista Strategies27 funds on PPLI.com | USD 2.1m | 0.5% |
| 36 | Dark Forest Capital Management2 funds on PPLI.com | USD 1.3m | 0.1% |
| 37 | Capricorn Fund Managers8 funds on PPLI.com | USD 1.3m | 0.1% |
| 38 | Magnetar Financial93 funds on PPLI.com | USD 1.1m | 0.0% |
| 39 | Campbell & Company Investment Adviser8 funds on PPLI.com | USD 913,000 | 0.0% |
| 40 | Entrypoint Capital1 fund on PPLI.com | USD 795,000 | 0.2% |
| 41 | Brevan Howard Capital Management39 funds on PPLI.com | USD 600,000 | 0.0% |
| 42 | Capstone Investment Advisors25 funds on PPLI.com | USD 539,000 | 0.0% |
| 43 | Hudson Bay Capital Management8 funds on PPLI.com | USD 529,000 | 0.0% |
| 44 | Oxford Asset Management LLP2 funds on PPLI.com | USD 214,000 | 0.1% |
| 45 | Bayforest Capital1 fund on PPLI.com | USD 189,000 | 0.2% |
A large manager can hold a great deal of a share and barely notice it. This table turns the question round and ranks managers by how much of their own book the position takes up.
| # | Manager | Value reported | Share of its book |
|---|---|---|---|
| 1 | Avoro Capital Advisors | USD 349m | 3.1% |
| 2 | Dafna Capital Management | USD 15m | 2.9% |
| 3 | Octagon Capital Advisors | USD 30m | 2.7% |
| 4 | Braidwell | USD 68m | 2.5% |
| 5 | Rock Springs Capital Management | USD 41m | 2.0% |
| 6 | Logos Global Management | USD 27m | 1.2% |
| 7 | Orbimed Advisors | USD 54m | 1.0% |
| 8 | Redmile Group | USD 14m | 0.9% |
| 9 | Sphera Funds Management | USD 6.3m | 0.8% |
| 10 | Artia Global Partners | USD 3.9m | 0.7% |
Xenon Pharmaceuticals Inc. trades under the symbol XENE on the Nasdaq. Its CUSIP, the code used on Form 13F, is 98420N105.
45 of the 720 hedge fund managers PPLI.com tracks reported Xenon Pharmaceuticals Inc. shares on Form 13F for 30 June 2026. The largest reported positions were held by Avoro Capital Advisors (USD 349m), Polar Capital LLP (USD 276m), Two Sigma Investments (USD 99m), Citadel Advisors (USD 85m) and Braidwell (USD 68m).
45 managers in our coverage reported it, and between them they run 603 funds with a file on PPLI.com. The count is of managers, because Form 13F is filed by the firm and not by each fund.
Avoro Capital Advisors, where the position was 3.1% of the reported 13F book at 30 June 2026.
No. Form 13F reports long positions in U.S.-listed shares and options. Short positions are not disclosed in it.
Positions are taken by PPLI.com from Form 13F filings with the U.S. Securities and Exchange Commission for the quarter shown. They are reported by each manager, cover all of its accounts and may have changed since. PPLI.com has no relationship with Xenon Pharmaceuticals Inc. or with the managers listed.
Nothing here is investment, tax or legal advice, a recommendation, or an offer or solicitation to buy or sell any security. To report an error, write to the editor.
Read our Privacy Policy before submitting. Share only the information needed to describe your question; do not include medical records or account credentials.